DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Beacon Investment Advisory Services Inc.

Beacon Investment Advisory Services Inc. reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 8.1% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 632,728 shares of the medical device company’s stock after selling 56,138 shares during the period. DexCom comprises approximately 2.1% of Beacon Investment Advisory Services Inc.’s portfolio, making the stock its 9th biggest position. Beacon Investment Advisory Services Inc. owned about 0.16% of DexCom worth $49,207,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of DXCM. Teamwork Financial Advisors LLC lifted its position in shares of DexCom by 49.7% during the fourth quarter. Teamwork Financial Advisors LLC now owns 18,729 shares of the medical device company’s stock valued at $1,457,000 after purchasing an additional 6,221 shares in the last quarter. Janney Montgomery Scott LLC increased its stake in DexCom by 2,226.6% in the 4th quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company’s stock valued at $18,085,000 after buying an additional 222,548 shares during the last quarter. Park Place Capital Corp lifted its position in shares of DexCom by 3,516.7% during the 4th quarter. Park Place Capital Corp now owns 868 shares of the medical device company’s stock worth $68,000 after buying an additional 844 shares in the last quarter. Advisory Alpha LLC bought a new position in shares of DexCom in the fourth quarter valued at approximately $205,000. Finally, MBM Wealth Consultants LLC purchased a new stake in shares of DexCom during the fourth quarter valued at approximately $465,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of recent analyst reports. Royal Bank of Canada reduced their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Leerink Partners reduced their price target on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Raymond James lowered their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Finally, Sanford C. Bernstein lifted their price target on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.29.

DexCom Stock Up 0.9 %

Shares of NASDAQ DXCM opened at $87.09 on Thursday. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The company has a market cap of $34.02 billion, a P/E ratio of 52.15, a P/E/G ratio of 2.26 and a beta of 1.12. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The business has a 50-day simple moving average of $78.70 and a two-hundred day simple moving average of $77.37.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.